Emerging market solutions for financing and reimbursement of gene therapies for sickle cell disease: Why do payment innovation?

Eric NormanFoCUS, Research Briefs


The FDA has approved two cell and gene therapies for sickle cell disease, marking a significant development for the largest population condition to date. ​ However, the high treatment costs, budget impact, and unique challenges of SCD create a need for payment innovation to ensure access and sustainability for all stakeholders. ​

NEWDIGS SCD Payment Innovation 1 2024F202v058.pdf

Share the research